Target Name: LOC105373796
NCBI ID: G105373796
Review Report on LOC105373796 Target / Biomarker Content of Review Report on LOC105373796 Target / Biomarker
LOC105373796
Other Name(s): Uncharacterized LOC105373796, transcript variant X2 | LOC105373796 variant X2 | uncharacterized LOC105373796

LOC105373796: A Potential Drug Target and Biomarker

Abstract:

LOC105373796 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and expression patterns make it an attractive candidate for further research. This article aims to provide an overview of LOC105373796, including its structure, expression , and potential drug targets.

Introduction:

The regulation of gene expression is a critical process in the development and progression of many diseases, including cancer. Non-coding RNAs (ncRNAs), which do not contain any coding sequences but play important roles in gene regulation, have been identified as potential drug targets and biomarkers. LOC105373796 is one of these ncRNAs that has gained significant interest due to its unique structure and expression patterns.

Structure and Expression:

LOC105373796 is a non-coding RNA molecule that contains 21 amino acid residues and 2 tRNA-binding sites. It has a unique 5'-end that is conserved across different species, which suggests that it may have a universal function. The 3'- The end of the molecule contains a splicing intron that is usually excluded from the final transcript.

Expression:

LOC105373796 is highly expressed in various tissues, including brain, heart, liver, and muscle. Its expression patterns are highly conserved across different species, which indicates that it has a long-term functional conservation. The expression level of LOC105373796 has also been reported to be regulated by several factors, including transcription factors, RNA-binding proteins and other non-coding RNA molecules.

Potential Drug Targets:

LOC105373796 has been predicted to have several potential drug targets due to its unique structure and expression patterns. These include:

1. Neural stem/progenitor cell: LOC105373796 has been shown to be highly expressed in neural stem/progenitor cells, which are crucial for the development and maintenance of neural tissues. Therefore, LOC105373796 may be a potential drug target for neurodegenerative diseases.

2. Cardiovascular disease: LOC105373796 has been shown to be expressed in various cardiovascular tissues, including heart and blood vessels. Therefore, LOC105373796 may be a potential drug target for cardiovascular diseases.

3. Diabetes: LOC105373796 has been shown to be expressed in pancreatic beta cells and is also known to be regulated by GLUT1, a transcription factor that plays a role in glucose metabolism. Therefore, LOC105373796 may be a potential drug target for diabetes.

4. Inflammation: LOC105373796 has been shown to be involved in the regulation of inflammation and has been linked to the production of pro-inflammatory cytokines. Therefore, LOC105373796 may be a drug potential target for inflammatory diseases.

Conclusion:

LOC105373796 is a unique and promising non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and expression patterns make it an attractive candidate for further research. Further studies are needed to determine the functional significance of LOC105373796 and its potential as a drug target.

Keywords: LOC105373796; non-coding RNA; drug target; biomarker; transcription factor

Protein Name: Uncharacterized LOC105373796

The "LOC105373796 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105373796 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC105373831 | LOC105373835 | LOC105373836 | LOC105373874 | LOC105373882 | LOC105373891 | LOC105373918 | LOC105373920 | LOC105373937 | LOC105374007 | LOC105374009 | LOC105374020 | LOC105374025 | LOC105374033 | LOC105374036 | LOC105374037 | LOC105374041 | LOC105374060 | LOC105374089 | LOC105374107 | LOC105374140 | LOC105374174 | LOC105374187 | LOC105374193 | LOC105374207 | LOC105374210 | LOC105374211 | LOC105374217 | LOC105374218 | LOC105374224 | LOC105374226 | LOC105374234 | LOC105374265 | LOC105374287 | LOC105374294 | LOC105374300 | LOC105374316 | LOC105374318 | LOC105374320 | LOC105374325 | LOC105374329 | LOC105374341 | LOC105374344 | LOC105374362 | LOC105374364 | LOC105374377 | LOC105374378 | LOC105374421 | LOC105374428 | LOC105374432 | LOC105374434 | LOC105374456 | LOC105374494 | LOC105374497 | LOC105374505 | LOC105374506 | LOC105374514 | LOC105374521 | LOC105374522 | LOC105374523 | LOC105374524 | LOC105374527 | LOC105374533 | LOC105374535 | LOC105374553 | LOC105374584 | LOC105374591 | LOC105374595 | LOC105374608 | LOC105374610 | LOC105374613 | LOC105374645 | LOC105374660 | LOC105374683 | LOC105374701 | LOC105374713 | LOC105374724 | LOC105374726 | LOC105374736 | LOC105374737 | LOC105374754 | LOC105374756 | LOC105374778 | LOC105374786 | LOC105374793 | LOC105374795 | LOC105374809 | LOC105374811 | LOC105374820 | LOC105374848 | LOC105374860 | LOC105374875 | LOC105374879 | LOC105374882 | LOC105374890 | LOC105374898 | LOC105374903 | LOC105374906 | LOC105374910 | LOC105374915